Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa
(Thomson Reuters ONE) -
Vifor Pharma Ltd. /
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of
Relypsa
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Galenica Group today announced that its tender offer to purchase the outstanding
shares of common stock of Relypsa, Inc., (NASDAQ: RLYP) at USD 32.00 per share,
net to the seller in cash, without interest and less any applicable withholding
taxes, expired at 12:00 midnight New York time, at the end of the day on
Wednesday, August 31, 2016. The tender offer was effected by Galenica's indirect
wholly owned subsidiary, Vifor Pharma USA Inc.
The depositary for the tender offer has advised that, as of the expiration of
the tender offer, a total of 38,673,841 shares of Relypsa's outstanding common
stock have been validly tendered and not validly withdrawn (not including any
shares tendered pursuant to notices of guaranteed delivery), representing
approximately 85.6% of Relypsa's outstanding shares. In addition, the depositary
advised that notices of guaranteed delivery have been delivered with respect to
1,842,226 additional shares, representing approximately 4.1% of Relypsa's
outstanding shares. All shares that were validly tendered and not validly
withdrawn during the offer period have been accepted for payment. Payment for
such shares will be made promptly, in accordance with the terms of the offer.
The condition to the tender offer that a majority of Relypsa's outstanding
shares be validly tendered has now been satisfied, and Galenica intends to
complete its acquisition of Relypsa promptly through a merger under Section
251(h) of the General Corporation Law of the State of Delaware. As a result of
the merger, each share of common stock of Relypsa not tendered in the tender
offer (other than shares held by Relypsa, Galenica or their respective wholly
owned subsidiaries and other than shares held by Relypsa stockholders who have
properly and validly perfected their statutory appraisal rights in connection
with the merger in compliance with Delaware law) will be converted into the
right to receive USD 32.00 per share, net to the seller in cash, without
interest and less any applicable withholding taxes.
For further information, please contact:
Galenica Media Relations:
Christina Hertig, Head Corporate Communications
Tel.: +41 58 852 85 17
E-mail: media(at)galenica.com
Galenica Investor Relations:
Jörg Kneubühler, Chief Financial Officer
Tel.: +41 58 852 85 29
E-mail: investors(at)galenica.com
Vifor Pharma Media Relations:
Beatrix Benz, Head of Global Communications & Public Affairs
Tel.: +41 58 851 80 16
E-mail: media(at)viforpharma.com
Galenica is a diversified Group active throughout the healthcare market which,
among other activities, develops, manufactures and markets pharmaceutical
products, runs pharmacies, provides logistical and database services and sets up
networks. With its two Business units Vifor Pharma and Galenica Santé, the
Galenica Group enjoys a leading position in all its core business activities. A
large part of the Group's income is generated by international operations.
Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN,
security number 1,553,646).
Additional information concerning the Galenica Group can be found at
www.galenica.com.
Vifor Pharma, a company of the Galenica Group, is a world leader in the
discovery, development, manufacturing and marketing of pharmaceutical products
for the treatment of iron deficiency. The company also offers a diversified
portfolio of prescription medicines as well as over-the-counter (OTC) products.
Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global
presence and a broad network of affiliates and partners around the world.
For more information about Vifor Pharma, please visit www.viforpharma.com.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery,
development and commercialisation of polymeric medicines for patients with
conditions that are often overlooked and undertreated and can be addressed in
the gastrointestinal tract. The Company's first medicine,
Veltassa(®) (patiromer) for oral suspension, was developed based on Relypsa's
rich legacy in polymer science. Veltassa is approved in the United States for
the treatment of hyperkalaemia. Veltassa has intellectual property protection
until 2030 in the United States and 2029 in the European Union.
More information is available at www.relypsa.com.
Forward Looking Statements
The statements included in this press release contain forward-looking
statements, which are generally statements that are not historical facts.
Forward-looking statements can be identified by the words "expects,"
"anticipates," "believes," "intends," "estimates," "plans," "will," "outlook"
and similar expressions. Forward-looking statements are based on management's
current plans, estimates, assumptions and projections and speak only as of the
date they are made. Galenica undertakes no obligation to update any forward-
looking statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve inherent risks and
uncertainties, most of which are difficult to predict and are generally beyond
the control of Galenica, including the following: (a) the risk that the
transaction disrupts current plans and operations; (b) difficulties or
unanticipated expenses in connection with integrating Relypsa into Galenica; (c)
the risk that the acquisition does not perform as planned; and (d) potential
difficulties in employee retention. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as a result of
the impact of a number of factors, many of which are discussed in more detail in
the public reports of each company filed with the SEC or the SIX Swiss Exchange.
Press Release (PDF):
http://hugin.info/148637/R/2038953/759938.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vifor Pharma Ltd. via GlobeNewswire
Datum: 01.09.2016 - 07:02 Uhr
Sprache: Deutsch
News-ID 492133
Anzahl Zeichen: 7088
contact information:
Town:
Glattbrugg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa"
steht unter der journalistisch-redaktionellen Verantwortung von
Vifor Pharma Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
